Sam­sung BioEpis pitch­es Her­ceptin biosim­i­lar as par­ent com­pa­ny hunts $2B IPO; Chi­as­ma CEO is out

In the lat­est ad­vance by a new wave of biosim­i­lars hit­ting reg­u­la­tors on both sides of the At­lantic, Sam­sung Bioepis says that it has filed for a Eu­ro­pean ap­proval of a knock­off of Her­ceptin. Bioepis is ma­jor­i­ty con­trolled by Sam­sung Bi­o­Log­ics, which just filed to raise up to $2 bil­lion in an IPO that val­ues the com­pa­ny at more than $8 bil­lion. Bio­gen owns 8.8% of the com­pa­ny un­der an ear­li­er deal to part­ner on de­vel­op­ment projects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER